Related references
Note: Only part of the references are listed.Species differences in lipoprotein lipase and hepatic lipase activities: comparative studies of animal models of lifestyle-related diseases
Norie Kimurai et al.
EXPERIMENTAL ANIMALS (2019)
Mapping Atheroprotective Functions and Related Proteins/Lipoproteins in Size Fractionated Human Plasma
Debi K. Swertfeger et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Update of the effect estimates for common variants associated with carotid intima media thickness within four independent samples: The Bonn IMT Family Study, the Heinz Nixdorf Recall Study, the SAPHIR Study and the Bruneck Study
Marie H. Geisel et al.
ATHEROSCLEROSIS (2016)
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles
Mike Mackness et al.
GENE (2015)
Glycation of Apolipoprotein C1 Impairs Its CETP Inhibitory Property: Pathophysiological Relevance in Patients With Type 1 and Type 2 Diabetes
Benjamin Bouillet et al.
DIABETES CARE (2014)
Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease
Xavier Pillois et al.
JOURNAL OF LIPID RESEARCH (2012)
Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein
David Masson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
HDL in humans with cardiovascular disease exhibits a proteomic signature
Tomas Vaisar et al.
CLINICA CHIMICA ACTA (2010)
Longitudinal Genome-Wide Association of Cardiovascular Disease Risk Factors in the Bogalusa Heart Study
Erin N. Smith et al.
PLOS GENETICS (2010)
APOE/C1/C4/C2 Gene Cluster Genotypes, Haplotypes and Lipid Levels in Prospective Coronary Heart Disease Risk Among UK Healthy Men
Gie Ken-Dror et al.
MOLECULAR MEDICINE (2010)
Apolipoprotein CI levels are associated with atherosclerosis in men with the metabolic syndrome and systemic inflammation
R. L. M. van der Ham et al.
ATHEROSCLEROSIS (2009)
Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma
Jean-Paul Pais de Barros et al.
JOURNAL OF LIPID RESEARCH (2009)
Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo
Willeke de Haan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Plasma apolipoprotein CI protects against mortality from infection in old age
Jimmy F. P. Berbee et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2008)
Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice
Marit Westerterp et al.
CIRCULATION (2007)
Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase
G. Dautin et al.
KIDNEY INTERNATIONAL (2007)
Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis
Jimmy F. P. Berbee et al.
FASEB JOURNAL (2006)
Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides
R de Vries et al.
DIABETES (2005)
Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI
L Dumont et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice
T Gautier et al.
BIOCHEMICAL JOURNAL (2005)
Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice
T Gautier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Human apolipoprotein C-I accounts for the ability of plasma nigh density lipoproteins to inhibit the cholesteryl ester transfer protein activity
T Gautier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease
J Björkegren et al.
CIRCULATION (2000)
Share Paper
